Fabry Disease Epiomic Insights, 2015-2021
Epiomic Insights for Fabry Disease provides you with a top line snapshot of the market potential for this inherited rare disease. Consisting of a wide variety of symptoms, Fabry disease remains difficult for clinicians to diagnose until symptoms present more severely in adulthood. This disease can also affect other organs adding to the complexity of identifying and quantifying accurately the appropriate population that would be relevant for any new innovation aligned with this disease.
Sourcing data from our Epiomic Patient segmentation database, we are able to reference relevant clinical trial data and patient registries to provide a picture of the total projected prevalent population across 8 major global markets.
This one-page synopsis developed by our team of analysts delivers a current overview of the disease and risk factors with a perspective on the future drivers of the patient population. The total Fabry Disease population across all markets has also been segmented by gender type and types of hearing impairments in an easy to understand graphical chart.
This style of report is ideal for companies entering a new market segment or disease area of which they have limited knowledge. Alternatively, companies considering investing in healthcare innovation may benefit from a high-level, accurate overview of the market to determine likely commercial potential of such an investment.
Sourcing data from our Epiomic Patient segmentation database, we are able to reference relevant clinical trial data and patient registries to provide a picture of the total projected prevalent population across 8 major global markets.
This one-page synopsis developed by our team of analysts delivers a current overview of the disease and risk factors with a perspective on the future drivers of the patient population. The total Fabry Disease population across all markets has also been segmented by gender type and types of hearing impairments in an easy to understand graphical chart.
This style of report is ideal for companies entering a new market segment or disease area of which they have limited knowledge. Alternatively, companies considering investing in healthcare innovation may benefit from a high-level, accurate overview of the market to determine likely commercial potential of such an investment.
